1. Russell T, Stein DS, Kazierad DJ (2011) Design, conduct an analysis of thorough QT studies. In: Bonate PL, Howard DR (eds) Pharmacokinetics in drug development: advances and applications. Springer, New York, pp 211–241
2. European Agency for the Evaluation of Medicinal Products (1997) Points to Consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products.
https://www.fda.gov/ohrms/dockets/ac/03/briefing/pubs/cpmp.pdf
. Accessed on 29 March, 2017
3. Britto MR, Sarapa N (2016) Clinical QTc assessment in oncology. In: Bonate PL, Howard DR (eds) Problems and challenges in oncology, vol 4. Springer International Publisher, Dordrecht, pp 77–106
4. Garnett CE, Beasley N, Bhattaram VA et al (2008) Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol 47:13–18
5. United States Department of Health and Human Services, Food and Drug Administration, and Center for Drug Evaluation and Research (2005) Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (E14).
https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf
. Accessed on 29 March, 2017